0001193125-26-215740
SEC filingPersistent losses narrowed amid R&D efficiencies and pipeline prioritization, with collaboration revenue dipping due to AvenCell recognition changes, while positive Phase 3 lonvo-z data advances 2027 commercial preparations.
Collaboration revenue decreased 9.5% year-over-year to $15.0 million in Q1 FY2026 from $16.6 million, primarily due to lower revenue recognition under the license and collaboration agreement with AvenCell Therapeutics, Inc. As a clinical-stage biotech dependent on partnerships for all topline growth, this decline highlights the impact of milestone timing and partner-specific progress. The dip underscores revenue volatility inherent in collaboration-driven models but remains at levels sufficient to support core operations amid pipeline advancement.
Operating loss narrowed 16.8% to -$100.5 million from -$120.8 million, driven by R&D efficiencies as the Company focuses resources on high-value programs like lonvo-z for hereditary angioedema (HAE) and nex-z for ATTR amyloidosis. This aligns with expectations for R&D expense decreases in 2026 through program prioritization and efficient execution toward near-term clinical milestones and commercial readiness. Net loss improved 15.8% to -$96.2 million, with diluted EPS loss shrinking 26.4% to -$0.81 from -$1.10, reflecting these cost controls despite ongoing investments. The operating margin of -668.1% illustrates persistent unprofitability but shows progress in loss mitigation.